A 37-year-old white woman was referred to the Cleveland Clinic Foundation for evaluation of a right suprarenal mass. BeginningS years before, she had experienced episodes of severe headache, pounding heart, and flushing, followed by facial pallor and tremulousness. Neither blood pressure nor heart rate was checked during these spells. The attacks occurred about twice monthly and lasted for 5 to 20 minutes. She noted that "bearing down" during defecation or "curling up" on her left side often precipitated these episodes.
production of vasoactive intestinal peptide [5, 61; and cushingoid features, accompanied by severe hypokalemic alkalosis, can arise from overproduction of ACTH [7] [8] [9] .
Some patients present with an acute surgical abdomen due to bowel ischemia and/or hemorrhagic necrosis of the tumor [10] [11] [12] [13] [14] . Others present with constant abdominal pain associated with marked hypertension followed by hypotension and even shock and sudden death [13, 14] . Sudden death probably results from marked arterial and venous dilation due to sudden withdrawal of catecholamines, the hypotension being compounded by the presence of intravascular hypovolemia. Overt diabetes can occur in patients with pheochromocytoma because catecholamines antagonize insulin release [15] . Lactic acidosis in the absence of shock should arouse suspicion of pheochromocytoma [16] . The increase in lactate production is thought to reflect a direct stimulation by epinephrine associated with decreases in oxygen delivery and increases in oxygen utilization.
Cardiovascular abnormalities occur commonly in patients with pheochromocytomas, the commonest probably being myocarditis [171. Patients often present with signs and symptoms like those observed in acute myocardial infarction [18] . Cardiac arrhythmias, including atrial and ventricular fibrillation, can be precipitated by anesthetic agents or surgery for unrelated conditions. These arrhythmias probably are due to the sudden release of catecholamines. Dilated congestive cardiomyopathy, believed to be related to myocarditis, has been described in some patients [17] . Pulmonary edema, which can be either cardiogenic or noncardiogenic in origin, can be the first manifestation of a pheochromocytoma. Noncardiogenic pulmonary edema is believed to result from transient increases in pulmonary capillary pressure due to pulmonary venoconstriction and increased pulmonary capillary permeability [19, 20] .
Altered mental status, focal neurologic signs and symptoms, and/or seizures occasionally are observed during a hypertensive crisis [I] . Stroke due to cerebral infarction, intracerebral hemorrhage resulting from severe arterial hypertension, and/or emboli secondary to mural thrombus from a dilated cardiomyopathy also can complicate pheochromocytoma. Finally, certain drugs sometimes precipitate a hypertensive crisis in patients harboring a pheochromocytoma. Such drugs include tricyclic antidepressants [21] . antidopaminergic agents (for example, sulpiride) and metoclopramide [221, and naloxone [23] .
Unrelated disorders are likely to be confused with pheochromocytoma on the basis of catecholamine levels (Table 1) . Angina pectoris, acute clonidine withdrawal, hypoglycemia, and vasodilator therapy (with either minoxidil or hydralazine)
can produce plasma catecholamine values as high as those observed in pheochromocytoma [24] . The fact that pheochromocytomas can present in many ways explains why so many of these tumors are missed. In a series from the Mayo Clinic, 41 of the 54 autopsy-proven cases were unsuspected clinically during life [25] . Of the 13 (of the 54 cases) correctly diagnosed before death, 4 cases were discovered incidentally at laparotomy for unrelated conditions. Of those diagnosed after death, only 54% had had hypertension. Headaches (27%), diaphoresis (17%), and palpitations (17%) were much less common than in patients whose tumor was diagnosed before death. Twelve patients were older than 68 years; in 9 of these elderly patients, the diagnosis was unsuspected. In a retrospective study from Australia. 29 of 46 proven cases were diagnosed and treated during life, whereas 17 were diagnosed at 546 Nephrologv Forum: Pheochromocvtoma autopsy [26] . Of the latter, 14 died of cardiovascular complications that were attributed to their disease. Most of the tumors discovered at autopsy were found in patients 60 years or older. with pheochromocytoma present with minor or no signs and symptoms. Further, elderly patients appear to present a special diagnostic challenge. A contributory factor to the rarity of the antemortem diagnosis of pheochromocytoma in the elderly may be a decrease in sensitivity to catecholamines with age. Additionally, most elderly patients have concomitant disease, the signs and symptoms of which can confound the diagnosis.
Cardiac and neurologic symptoms often are attributed to coronary artery and cerebrovascular disease from atherosclerosis.
New concepts in pathophysiology At first blush, the mechanism of elevated blood pressure in patients with pheochromocytoma might seem to be the most straightforward of all the secondary forms of hypertension. Surprisingly, however, approximately 15% of patients are normotensive [29] . In addition, no relationship exists between the prevailing levels of plasma catecholamines and the height of arterial blood pressure (Fig. 3) Prolonged stimulation of a tissue by adrenergic agonists can diminish responsiveness of the tissue to subsequent activation by catecholamines; this phenomenon has been termed desensitization, or tachyphylaxis. Tsujimoto and colleagues examined the in-vivo consequences of prolonged stimulation of vascular alpha-adrenergic receptors in rats harboring norepinephrineproducing tumors [321. In the early stages of the disease, sensitivity was lost for both al-and a2-adrenergic agonists, whereas responsiveness to arginine vasopressin and angiotension II was intact. Additionally, radioligand binding studies showed that the number of crl-adrenergic receptors decreased by 36% in mesenteric artery plasma membrane from these rats, whereas the number of s2-adrenergic receptors was unaltered. These results provide a plausible explanation for the observation that patients can be normotensive or only moderately hypertensive despite high circulating levels of catecholamines.
It has always been assumed that sympathetic nerve activity in patients with pheochromocytoma would be depressed because of the high circulating catecholamines. However, both clinical and experimental evidence suggests that the sympathetic nervous system plays a significant role in the maintenance of hypertension in patients with pheochromocytoma. The clinical evidence for this conclusion comes from our studies of the effects of orally administered clonidine in patients with either essential hypertension or pheochromocytoma [33] . Clonidine, a centrally acting cr2-agonist, inhibits neurally mediated catecholamine release. Clonidine decreases blood pressure to the same degree in patients with pheochromocytoma as it does in those with essential hypertension. These results suggest that the sympathetic nervous system is intact in pheochromocytoma. In essential hypertension, the fall in blood pressure is associated with decreases in circulating catecholamines, but in pheochromocytoma, plasma catecholamine levels do not change [331.
The discrepancy between the fall in blood pressure in patients with pheochromocytoma after clonidine administration and the persistently high levels of circulating catecholamines suggests that the norepinephrine released from axon terminals of sympathetic postganglionic neurons is biologically more significant than circulating catecholamines. This discrepancy could be related to the easier access of norepinephrine released from postganglionic neurons to its site of action at effector cells.
Neural control of blood pressure also exists in rats implanted with a pheochromocytoma. Eliminating sympathetic nerve activity by pithing caused a greater reduction of blood pressure in pheochromocytoma-bearing rats than in age-matched, unimplanted rats [32] . Additionally, Prokocimer and coworkers found that both clonidine and chlorisondamine (a ganglion blocker) markedly decreased blood pressure in intact rats with pheochromocytoma [34] . However, the observation that the blood pressure in pithed rats with pheochromocytoma is further reduced by phentolamine, an alpha-adrenergic antagonist, suggests that high concentrations of circulating catecholamines also are involved in the maintenance of the elevated blood pressure. Thus, the hypertension in pheochromocytoma is a complex process influenced by the sympathetic nervous system, by circulating catecholamines, and by alterations in cardiovascular responses to catecholamines.
Our studies of the hemodynamics of hypertension reveal that despite having tenfold higher levels of circulating catecholamines, patients with pheochrornocytoma have hemodynamic characteristics similar to those in patients with essential hypertension [35] . In both groups, increased total peripheral resistance is primarily responsible for maintenance of hypertension. These results further support the concept that the sympathetic nervous system regulates blood pressure in both groups of patients. Orthostatic hypotension occurs in about 40% of patients with pheochromocytoma and probably is caused by a combination of hypovolemia and impaired venous and arterial constrictor reflex responses. However, blood volume does not differ between patients who exhibit postural hypotension and those who do not. In patients who develop significant blood pressure reductions on standing, the most consistent hemodynamic changes were decreases in systolic arterial pressure (without changes in diastolic blood pressure) and decreases in cardiac output without any compensatory increase in total peripheral resistance [361. These observations suggest impaired vascular reflexes, but it is unclear why some patients have this hemodynamic abnormality and some do not.
Experimental studies suggest that catecholamines increase protein synthesis and might play a role in cardiac hypertrophy [37] . However, patients with pheochromocytoma had leftventricular-mass indices similar to those in patients with ageand sex-matched essential hypertension who had tenfold lower plasma catecholamine values [38] .
Evaluation for suspected pheochromocytoma Priority for evaluation for the presence of pheochromocytoma should be given to patients with any of the following: (I) the triad of episodic headaches, tachycardia, and diaphoresis (with or without associated hypertension); (2) family history of pheochromocytoma; (3) signs or symptoms indicating a multiple endocrine adenoma (MEA) syndrome; (4) "incidental" suprarenal masses; (5) hypertension associated with equivocal increases in catecholamine production; and (6) adverse cardiovascular manifestations in response to anesthesia, to any surgical procedure, or to certain medications known to precipitate symptoms in patients with pheochromocytoma.
Biochemical tests. The most useful urine tests measure concentrations of metanephrine, vanillylmandelic acid (VMA), and free (unconjugated) catecholamirtes. These tests have been compared in patients with confirmed pheochromocytoma and in hypertensive patients without the tumor. In 43 patients with tumors, the false-negative rates were 30% for urinary VMA and 10% for urinary metanephrines [39] . In another study, none of 25 patients with pheochromocytoma had a false-negative rate for urinary free norepinephrine [401. Thus, assays of 24-hour urinary catecholamines and metanephrines are adequate for diagnosing pheochromocytoma in most patients.
Sole reliance on determination of urinary catecholamine metabolites as indices of catecholamine production can be misleading, however. The amounts and types of metabolites excreted in urine depend on a number of factors. First, the handling of catecholamines by the kidney depends on both degradation and excretion [41] . Second, in patients with pheochromocytoma, the activities of the enzymes involved in catecholamine synthesis (tyrosine hydroxylase, aromatic amino acid decarboxylase, and dopamine 13-hydroxylase) are markedly increased, whereas the activities of the enzymes involved in catecholamine catabolism (monoamine oxidase and catecholo-methyltransferase) are reduced [42] . Thus, excess amounts of newly synthesized norepinephrine that cannot be stored in the filled catecholamine storage vesicles are not always degraded, and the norepinephrine diffuses from the pheochromocytoma into the circulation. This efflux could result in large amounts of circulating norepinephrine with relatively small increases in urinary catecholamine metabolites. Third, the size of the tumor is an important determinant of the relative amounts of catecholamine excretory products. Crout and Sjoerdsma demonstrated that tumors weighing less than 50 g have rapid turnover rates and release mainly unmetabolized catecholamines into the circulation, producing low concentrations of metabolites relative to free catecholamines in the urine [43] . On the other hand, tumors weighing more than 50 g have slow turnover rates and release mainly metabolized catecholamines into the circulation, resulting in high concentrations of inetabolites relative to free catecholamines in the urine. These observations have important clinical implications. Because small tumors release free unmetabolized catecholamines into the circulation, they tend to produce more symptoms and are best diagnosed by the measurement of plasma catecholamines. In contrast, patients who have large tumors that metabolize most of the secreted catecholamines exhibit few symptoms and have relatively lower circulating free catecholamines but high urinary excretions of catecholamine metabolites.
Figures 4 and 5 depict plasma catecholamine levels in a group of patients with pheochromocytoma; these values are compared with those from patients with essential hypertension [44] . It is clear that the majority of patients with pheochromocytoma abnormal result was an elevated plasma catecholamine level. These findings are in accord with the demonstration of variable metabolism and degradation of catecholamines in pheochromocytomas. Further, these results suggest that of the urinary catecholamine metabolites, urinary metanephrine provides a more reliable clue to the presence of pheochromocytoma than does urinary VMA, and that plasma catecholamine measurements are at least as reliable as is measurement of urinary metanephrine in predicting the presence of pheochromocytoma. Catecholamine values in normotensive and hypertensive subjects are shown in Table 2 . The sensitivity and specificity of the various biochemical tests appear in Table 3 . Measurement of plasma catecholamines seems to have the highest sensitivity and specificity; the measurement of urinary VMA has the lowest. All three tests provide excellent positive predictive value when values are elevated, however.
The availability of tests in any given center necessarily determines the nature of the investigation in an individual patient, and debate over the relative merits of various tests will continue. However, it seems likely that for 100% diagnostic accuracy, multiple tests may have to be performed taking into account the limitations and pitfalls of some analytical methods.
Because the metabolism of catecholamines in patients with pheochromocytoma may be modified by either a lack or an excess of metabolizing enzymes, plasma catecholamines as well as catecholamine metabolites in urine (preferably metanephrine) should be measured in equivocal cases.
Plasma chromogranin A concentration has been proposed as a diagnostic test for pheochromocytoma: plasma levels are about tenfold higher than those in other hypertensive patients [451. Chromogranin A is a soluble protein contained in catecholamine storage vesicles. Because it is released simultaneously with norepinephrine, its level in plasma reflects sympathoadrenal activity [46] . But chromogranin A also is found in blood of patients with other neuroendocrine tumors [47] . Because platelets concentrate catecholamines [481, patients with pheochromocytoma have increased platelet norepinephrine and epinephrine content. Zweifler and Julius have suggested that platelet catecholamine content might discriminate between patients with pheochromocytoma and those with nonpheochromocytoma-associated hypertension [49] . A recent study showed, however, that the usefulness of platelet catecholamines in diagnosing pheochromocytoma is limited because of the high false-positive rates-36% for platelet norepinephrine and 19% for platelet epinephrine [50] .
The simultaneous measurement of urinary norepinephrine and 3,4-dihydroxyphenylglycol (DHPG) has been proposed as a means of increasing the specificity of urine testing. Norepinephrifle that is released by neurons is again taken up and converted to DHPG [511. Therefore, DHPG levels reflect the extent of neuronal traffic. In patients with pheochromocytoma, however, norepinephrine is released directly into the circulation and results in higher ratios of norepinephrine/DHPG than observed in other hypertensive patients [52] . Measuring free norepineph- risky, the test can be performed with the patient receiving either a calcium antagonist or an aipha-adrenergic blocking drug.
In patients with moderate increases in plasma catecholamines (between 1000 and 2000 pg/mI), a suppression test should be employed. The clonidine suppression test is based on the capacity of clonidine, a centrally acting a2-adrenergic agonist, to suppress the release of neurogenically mediated catecholamine release [54] . The test is based on the principle that normal increases in plasma catecholamines are mediated through activation of the sympathetic nervous system. In patients with pheochromocytoma, however, the increases result from the diffusion of excess catecholamines from the tumor into the circulation, bypassing the normal storage and release mechanisms. Clonidine therefore should not suppress the release of catecholamines in patients with pheochromocytoma. Figure 7 shows the results of the clonidine suppression test in patients with proven pheochromocytoma [44] . The results were compared with those of gender-matched and age-matched subjects with essential hypertension. Of the 40 patients, 27 had adrenal pheochromocytoma and 13 had extra-adrenal pheochromocytoma. After clonidine was administered, plasma catecholamine values fell below 500 pg/mi in all but one patient with essential hypertension. In contrast, in all but one patient with a pheochromocytoma, plasma catecholamine values remained above 500 pg/mI after clonidine admiuistration. According to this experience, a normal clonidine suppression test should consist of a fall in the values of plasma norepinephrine plus epinephrine to a level below 500 pg/mI at 2 or 3 hours after the oral administration of 0.3 mg of clonidine. It is important to record blood pressure and heart rate responses and any effects related to the central nervous system, because certain signs and symptoms (such as drowsiness, thirst, and reductions in blood pressure and heart rate) reflect the completeness of the gastrointestinal absorption of clonidine.
Hypotension is a potential hazard of the clonidine suppression test, but symptomatic hypotension is not a problem in the untreated patient. All reported cases of severe hypotension have occurred in patients who were receiving antihypertensive medications or who had other conditions that would tend to augment the effects of any antihypertensive agents [55, 56] . In particular, the test should not be carried out in a patient with marked volume depletion. In addition, administration of any beta-adrenergic blocking agent should be discontinued approximately 48 hours before the test is performed. Clonidine has a potent vagotonic effect, so concomitant beta-adrenergic blockade could lead to marked bradycardia, further decreases in stroke volume and cardiac output, and severe hypotension. In addition, beta-adrenergic blockers can prevent the plasmacatecholamine-lowering effect of clonidine in a patient without pheochromocytoma because of the ability of such agents to interfere with hepatic clearance of catecholamines [57] .
Tumor localization. Tumor localization not only confirms the diagnosis of pheochromocytoma but also assists the surgeon in planning the surgical strategy. Advances in noninvasive imaging techniques now provide a safe and reliable means of localizing pheochromocytomas anywhere in the body. Computed tomographic (CT) scanning is the most widely applied and accepted modality for the anatomic localization of pheochromocytoma [58] ; it can accurately detect tumors larger than 1.0 cm. Because of its usual size, the tumor lends itself to visualization in virtually every instance in which the tumor is in the adrenal gland. Magnetic resonance imaging (MRI) is an alternative and has several advantages over CT scanning [59] .
First, it requires no radiation exposure. Second, MRI lends itself to in-vivo tissue characterization; pheochromocytomas, unlike other benign tumors that have a low signal intensity, demonstrate a high signal intensity on T2-weighted image [59, 60 ]. Third, MRI can differentiate tumor masses from surrounding vascular tissues, eliminating the need for the intravenous administration of contrast material. It is the procedure of choice in pregnant women because it poses no danger to the fetus, and in patients with surgical clips, which interfere with CT. Scintigraphic localization with radioiodinated metaiodobenzylguanidine (MIBG) provides both anatomic and functional characterization of a tumor [61] . However, because this compound is actively concentrated in sympathomedullary tissue through the catecholamine pump, the administration of drugs that block the reuptake mechanism (tricyclic antidepressants, guanethidine, and labetalol) can give false-negative results. Phenoxybenzamine, prazosin, propranolol, and calcium antagonists do not interfere with MIBG uptake.
A comparison of the three imaging techniques is shown in Table 4 . The data are from our prospective study involving 109 patients strongly suspected of having a pheochromocytoma [62] . All the patients had CT scanning and MIBG scintigraphy;
40 patients with tumor masses had, in addition, an MRI as a third localizing procedure. Forty-five patients had surgically proven pheochromocytoma, 20 had non-pheochromocytoma adrenal masses, and the remaining 44 were considered free of the disease after repeated biochemical testing and long-term followup. Based on the sensitivity, specificity, and predictive value of each of the three imaging techniques, the following sequence of localization is recommended. One should begin with an abdominal CT (including the pelvic region) with special attention to the adrenal gland. This is appropriate because 97% of pheochromocytomas are located in the abdominal area and 90% are intra-adrenal. In patients with demonstrable tumors, either MRI or MIBG scintigraphy should be performed next. Even if a primary adrenal pheochromocytoma is identified, MIBG can be useful in locating occult secondary or metastatic sites; such sites are present in approximately 10% of cases. Venous catheterization with selective sampling of blood for measurement of plasma catecholamine concentration at various sites along the superior and inferior vena cava is reserved for patients whose clinical and biochemical tests strongly suggest pheochromocytoma but in whom radiologic studies fail to locate the tumor [63] .
Treatment The goals of medical therapy are the treatment or prevention of cardiovascular complications and preparation of the patient for surgical intervention. The most frequently used therapeutic agent is phenoxybenzamine, a long-acting, non-competitive alpha-adrenergic blocker. Typically, treatment is initiated at 20 mg/day and increased stepwise to 80-100 mg/day as tolerated according to the severity of postural signs and symptoms (that is, hypotension, tachycardia, syncope, dizziness). Prazosin hydrochloride, a shorter-acting alpha-blocking agent, also has been used with some success [64] . Calcium antagonists are attractive agents because they are not only effective in controlling blood pressure, but they also are useful in managing cardiovascular complications [65] . They attenuate the pressor response to norepinephrine and can prevent catecholamineinduced coronary spasm and myocarditis. In addition, calcium antagonists have none of the complications associated with chronic use of alpha-adrenergic blockers. Beta-adrenergic blockers are added as needed to control tachycardia and arrhythmias. If beta blockade is absolutely contraindicated, either lidocaine or amiodarone can be used for serious rhythm disturbances [66] . Hypertensive crises can be managed with the parenteral administration of either phentolamine hydrochloride or sodium nitroprusside. Nicardipine, infused continuously at a rate of 2.5 to 7.5 zg/kg/min, prevents the severe hypertensive crises that usually occur during tumor manipulation at surgery, despite 3-to 85-fold increases in ciirculating catecholamines [67] .
Before surgery, every attempt must be made to minimize the possibility of intraoperative severe hypertension consequent to catecholamine release. The best drug for this purpose is phenoxybenzamine. Its theoretical advantages relate to its ability to permit vascular volume repletion and to block alpha receptors non-competitively, making it difficult for catecholamines released during surgery to overcome the drug's blocking effect [68, 69] . Conventional wisdom dictates that blood pressure should be controlled with phenoxybenzamine for at least 4 weeks before the surgical procedure. The stringent criteria However, a recent review of 60 of our patients with pheochromocytoma who underwent 63 surgical procedures disclosed that consistently successful surgical outcomes can be achieved without profound and prolonged aipha-adrenergic blockade preoperatively [71] . Of 29 patients who did not receive alpha-adrenergic blockade, there were no deaths or cerebral or cardiac complications. In addition, 80% of the patients required neither vasopressors nor vasodilators in the immediate postoperative period. Further, there were no differences in the length of stay in the postoperative acute care unit or in the duration of postoperative hospitalization between patients who received alpha blockers and those who did not. These favorable outcomes reflect the recent advances in anesthetic and monitoring techniques and the availability of fast-acting drugs capable of correcting sudden hemodynamic abnormalities.
Some postoperative complications require emphasis. The first is hypotension, which results from marked arterial and venous dilation consequent to the withdrawal of catecholamines and to the presence of diminished receptor sensitivity to endogenous catecholamines. Hypotension can be compounded 552 IVephrology Forum: Pheochromocytoma by previous postoperative alpha blockade and inadequate volume repletion; volume replacement, rather than vasopressors, is the primary treatment. Second, persistence of hypertension beyond 14 days after tumor excision should raise concern about residual or metastatic pheochromocytoma. If plasma catecholamines are still elevated at this time, the administration of clonidine (0.3 mg orally) will determine whether the hypertension is neurogenically mediated. Third. hypoglycemia can develop postoperatively because of excessive release of insulin previously inhibited by high levels of circulating catecholamines [721. In some instances, hypoglycemia can manifest as persistent hypotension resistant to pressor agents and volume repletion. The first goal of treatment is counteracting the effects of increased circulating catecholamines with alpha-or beta-adrenergic blocking drugs and/or calcium antagonists. The second is decreasing catecholamine synthesis by the tumor with alphamethyltyrosine, a "false" catecholamine precursor that inhibits the rate-limiting enzyme in catecholamine synthesis, tyrosine hydroxylase [74] . Whenever possible, surgical excision or dehulking of accessible tumors should be performed. This maneuver often helps decrease the levels of circulating catecholamines and provides easier control of blood pressure and other manifestations. Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine has been used in patients with advanced malignancy and is effective in suppressing the activity of some tumors [75] . However, the effect is only temporary. The administration of 311-MIBG to ablate primary and metastatic sites has been used with some success, with remissions and palliation having been reported [76] [77] [78] . However, initial therapeutic responses have not produced significant long-lasting benefit even with repeated administration [79] .
Questions and answers DR. JOHN T. HARRINGTON (Chief of Medicine, Neit'tonWellesley Hospital, Newton, Massachusetts): In the slides you showed on clinically unsuspected pheochromocytoma, it appears that approximately one-third of the pheos showed up only at postmortem; that is, a high percentage were unsuspected during life. Does that mean that they were endocrinologically active but were missed, or were those tumors not endocrinologically active at all? DR. BRAVO: The patients reported in the five articles were described as dying of cardiovascular complications usually associated with chronic hypertension. This indicates to me that the tumors were functional but that the diagnosis was not suspected before death. DR. HARRINGTON: You briefly alluded to studies of receptor assays in animals that had been treated with norepinephrine and epinephrine. Have any studies examined receptors in patients? Is there a way of doing such studies after a pheochromocytoma has been removed? What kind of down-regulation helps account for the 15% of patients who are normotensive? DR. BRAVO: One study reported that catecholamine resistance in fat cells from pheochromocytomas might be due to (1) the formation of a hormone antagonist, which modulates the cellular response to continuous stimulation by catecholamines or (2) an adaptive increase in phosphodiesterase activity, which modulates cellular sensitivity [801. In another study, Greenacre and Conolly found marked depression of lymphocytic betaadrenoreceptor responsiveness in 4 patients with proven pheochromocytoma [81] . The clinical relevance of such findings to the pheochromocytoma patients with normal pressure despite having high circulating catecholamines remains to be established.
DR. NIcOLA0s E. MADIAS (Chief Division of Nephrology, New England Medical Center, Boston, Massachusetts): I was impressed with the high sensitivity and specificity of the symptomatic triad of sweating attacks, tachycardia, and headache in a hypertensive patient in diagnosing pheochromocytoma as reported in a French study you cited [2] . I was wondering how rigorously the diagnosis of pheochromocytoma was pursued in that study that allowed the authors to arrive at those sensitivity and specificity rates? DR. BRAVO: In that particular study [2] , the investigators screened 2585 hypertensive patients for pheochromocytoma by recording the symptoms known to be those most associated with the disease, that is, headaches, palpitations, and sweating attacks. Only 6.5% (168 patients) reported all three symptoms; 72.4% of the entire patient population reported one or another of these complaints. Of the(168) patients who reported all three symptoms, 5,9% (10 patients) had pheochromocytoma. The 24-hour urinary VMA was the sole confirmatory test used in this study. Urinary VMA has poor sensitivity, so it is possible that some pheochromocytoma patients without the triad were DR. BRAVO: Our patients were referred to us because of signs and symptoms strongly suggestive of pheochromocytoma. In this highly selected group, the prevalence rate of the disease was about 41%; thus, signs and symptoms alone were poor predictors of the presence of pheochromocytoma in this group. I have no idea how common the triad (of headaches, sweating attacks, and tachycardia) was in our patients. We haven't yet extracted that information from the charts. It will be interesting to find out. DR The most important side effect associated with the glucagon stimulation test is the rapid rise in blood pressure, which is readily counteracted with phentolamine. Alternatively, the rise in blood pressure can be prevented by the administration of oral nifedipine 30 minutes before testing.
DR. MADIAS: We reported a patient with pheochromocytoma in whom severe lactic acidosis fealured prominently in the clinical presentation [831. High concentrations of epinephrine and norepinephrine have the potential for generating substantial hyperlactatemia on the basis of their metabolic and vasoconstrictor effects: both these influences result in overproduction and underutilization of lactate. DR. BRAVO: Severe lactic acidosis is an uncommon manifestation of pheochromocytoma, but it is a potential complication in patients with severe peripheral vasoconstriction. DR. Bivo: Any plasma catecholamine value that is obtained under less than optimal, standardized conditions has very little clinical utility. It is important that one record the blood pressure at the time of blood sampling because if the plasma catechoiamine level is less than 1000 pg/mI and the patient is markedly hypertensive, the diagnosis of pheochromocytoma is not likely. On the other hand, a plasma catecholamine level of 1000 pg/mi or less in the presence of a normal blood pressure does not rule out the disorder. As previously shown, however, blood pressure can be normal despite high circulating catecholamine levels in active pheochromocytoma.
